Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  2/25/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 2/25/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Enrolling
Updated:  2/25/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Enrolling
Updated: 2/25/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Enrolling
Updated:  2/25/2016
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Enrolling
Updated: 2/25/2016
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  2/25/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 2/25/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  2/26/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 2/26/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Sitagliptin Umbilical Cord Blood Transplant Study
A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Status: Enrolling
Updated:  2/26/2016
IU Simon Cancer Center
mi
from
Indianapolis, IN
Sitagliptin Umbilical Cord Blood Transplant Study
A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Status: Enrolling
Updated: 2/26/2016
IU Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated:  3/1/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated: 3/1/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated:  3/1/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated: 3/1/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
A Phase II Study of Rituximab Intense Dosing With CHOP-21 (RID-CHOP) in Patients With Previously Untreated High or High-Intermediate Risk IPI (3-5) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
A Phase II Study of Rituximab Intense Dosing With CHOP-21 (RID-CHOP) in Patients With Previously Untreated High or High-Intermediate Risk IPI (3-5) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Status: Enrolling
Updated:  3/3/2016
University of Michigan,Department of Internal Med. Hematology- Oncology
mi
from
Ann Arbor, MI
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Status: Enrolling
Updated: 3/3/2016
University of Michigan,Department of Internal Med. Hematology- Oncology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Status: Enrolling
Updated:  3/4/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Status: Enrolling
Updated: 3/4/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
University of California at Los Angeles UCLS School of Medicine
mi
from
Los Angeles, CA
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
University of California at Los Angeles UCLS School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Rocky Mountain Cancer Centers RMCC - Aurora
mi
from
Greenwood Village, CO
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Rocky Mountain Cancer Centers RMCC - Aurora
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Emory University School of Medicine/Winship Cancer Institute Emory University Med School
mi
from
Atlanta, GA
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Emory University School of Medicine/Winship Cancer Institute Emory University Med School
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer
mi
from
Chicago, IL
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Karmanos Cancer Institute Karmanos-1
mi
from
Detroit, MI
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Karmanos Cancer Institute Karmanos-1
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Mayo Clinic - Rochester Mayo Lymphoma Group
mi
from
Rochester, MN
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Mayo Clinic - Rochester Mayo Lymphoma Group
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201
mi
from
St. Louis, MO
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
Duke University Medical Center Duke University Med Ctr
mi
from
Durham, NC
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
Duke University Medical Center Duke University Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
University of Tennessee Cancer Institute Univ Tennessee Cancer
mi
from
Memphis, TN
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
University of Tennessee Cancer Institute Univ Tennessee Cancer
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3)
mi
from
Houston, TX
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3)
mi
from
Houston, TX
Click here to add this to my saved trials
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated:  3/8/2016
University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4
mi
from
Madison, WI
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Enrolling
Updated: 3/8/2016
University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4
mi
from
Madison, WI
Click here to add this to my saved trials
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)
Status: Enrolling
Updated:  3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)
Status: Enrolling
Updated: 3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Status: Enrolling
Updated:  3/8/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Status: Enrolling
Updated: 3/8/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Status: Enrolling
Updated:  3/8/2016
mi
from
Nantes Cedex 1,
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Status: Enrolling
Updated: 3/8/2016
mi
from
Nantes Cedex 1,
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Tri-Cities Cancer Center
mi
from
Kennewick, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Tri-Cities Cancer Center
mi
from
Kennewick, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
SCCA at EvergreenHealth
mi
from
Kirkland, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
SCCA at EvergreenHealth
mi
from
Kirkland, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Olympic Medical Center
mi
from
Port Angeles, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Olympic Medical Center
mi
from
Port Angeles, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Group Health Cooperative
mi
from
Redmond, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Group Health Cooperative
mi
from
Redmond, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Swedish Cancer Institute
mi
from
Seattle, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated:  3/8/2016
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
Enhancing Connections Telephone Program: A Cancer Education Program for Parents
Status: Enrolling
Updated: 3/8/2016
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  3/10/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 3/10/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  3/10/2016
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 3/10/2016
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Click here to add this to my saved trials
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  3/10/2016
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 3/10/2016
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Click here to add this to my saved trials
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  3/10/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 3/10/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials